Skip Navigation



Carcinogenesis Advance Access published online on February 6, 2008
Carcinogenesis, doi:10.1093/carcin/bgn028
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/4/824    most recent
bgn028v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mutoh, M.
Right arrow Articles by Wakabayashi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mutoh, M.
Right arrow Articles by Wakabayashi, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Plasminogen Activator Inhibitor-1 (Pai-1) Blockers Suppress Intestinal Polyp Formation in Min Mice

Michihiro Mutoh1, Naoko Niho1, Masami Komiya1, Mami Takahashi1, Rina Ohtsubo1, Kiyoshi Nakatogawa2, Kentaro Ueda2, Takashi Sugimura1 and Keiji Wakabayashi1

1 Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2 Shizuoka Coffein Co.LTD., 129 Suido-cho, Shizuoka-shi, 420-0008,Japan

Request for reprints: Michihiro Mutoh, Phone 3-3542-2511;Fax 3-3542-9305; E-mail: mimutoh{at}gan2.ncc.go.jp

Obesity and hyperlipidemia are known to increase colorectal tumor risk. We noticed that Min mice, featuring a defect in the Apc-gene, develop intestinal polyps along with high serum triglyceride (TG) levels up to 10-fold those observed in wild-type mice. In these mice, mRNA expression of lipoprotein lipase, which catalyzes hydrolysis of TG, is down-regulated. In the present study, we focused on adipocytokines, especially plasminogen activator inhibitor-1 (Pai-1), which is involved in hyperlipidemic status and may promote intestinal polyp formation in Min mice. Serum Pai-1 levels in 15 week-old male Min mice were 8 times higher than in wild-type mice and hepatic Pai-1 mRNA levels were 11-fold increased. In addition, Pai-1 immunostaining was strong in small intestinal epithelial cells of Min mice. Administration of a PAI-1 inhibitor, SK-216, at 25, 50 and 100 ppm doses in the diet for 9 weeks reduced serum Pai-1 levels and hepatic Pai-1 mRNA levels of Min mice to the wild-type levels. Moreover, SK-216 at 50 and 100 ppm significantly reduced total numbers of intestinal polyps to 64 and 56% of the untreated group value, respectively. Serum TG levels were also decreased by 43% at the dose of 100 ppm. Administration of 50 ppm SK-116, another PAI-1 inhibitor, for 9 weeks similarly reduced serum Pai-1 levels, and total numbers of intestinal polyps to 70% of the untreated group value. These results indicate that Pai-1 induction associated with hypertriglyceridemia may contribute to intestinal polyp formation with Apc-deficiency, and PAI-1 could thus be a novel target for colorectal chemopreventive agents.

Received August 10, 2007; revised January 23, 2008; accepted January 23, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. C.M. van Kruijsdijk, E. van der Wall, and F. L.J. Visseren
Obesity and Cancer: The Role of Dysfunctional Adipose Tissue
Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2569 - 2578.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.